Nicklaus Children’s Cancer Center is participating in a clinical trial of an investigational drug in children with metastatic tumors in the Ewing’s sarcoma family.
The multicenter Phase II randomized trial will compare the impact of Vigil™ cancer vaccine versus treatment using gemcitabine and docetaxel.
Patients meeting eligibility criteria must be:
- Two years of age or older
- Have documented evidence of Ewing’s sarcoma translocation
- Be intolerant to at least two lines of systemic chemotherapy
Other terms for Ewing’s sarcoma include Askin tumor and peripheral primitive neuroectodermal tumor (pPNET).
For more information on this trial, please complete the form below.